Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NR2E3 | Q9Y5X4 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809774 | 0.91 | KDR (0.57) | SCDKDRNPC1MAPTRAB9A | |
| SCHEMBL2805121 | 0.90 | SCD (0.71) | SCDKDRNPC1MAPTRAB9A | |
| SCHEMBL2803272 | 0.84 | SCD (0.71) | SCDKDRNPC1MAPTRAB9A | |
| SCHEMBL2317056 | 0.82 | SCD (0.79) | SCD | |
| SCHEMBL2803254 | 0.81 | SCD (0.54) | SCDKDRNR2E3EGFR | |
| SCHEMBL2807439 | 0.81 | SCD (0.69) | SCDKDRNR2E3EGFR | |
| SCHEMBL2804167 | 0.78 | SCD (0.73) | SCDKDRNPC1MAPTRAB9A | |
| SCHEMBL2316768 | 0.74 | SCD (0.59) | SCDKMT2AMEN1 | |
| SCHEMBL2316764 | 0.74 | CHEK2 (0.77) | SCDKMT2AMEN1 | |
| SCHEMBL2804175 | 0.74 | SCD (0.59) | SCDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | claimed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | SCD 3183/4885KDR 3982/4885NPC1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.